🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06263023
Active, not recruiting Observational

A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation

NCT06263023 · tracked via the Priya Life Science USA tracker
Sponsor
34 Lives, PBC
Phase
Observational
Started
2024-04-19
Last updated
2025-04-02

Condition(s) studied

Organ Preservation

Investigational drug(s) / intervention(s)

Sub-Normothermic Machine Preservation and Assessment

Sub-Normothermic Machine Preservation and Assessment: Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.

Study summary

This is a study to collect information to assess if transporting hard-to-place (HTP) donor kidneys to a central preservation and assessment facility with dedicated organ assessment capabilities increases allocation success to transplant hospitals.

Eligibility

Sex
ALL
Min age
16 Years
Max age
75 Years
Healthy volunteers
No
Donor Kidney Inclusion Criteria: * Be considered HTP, by receiving refusals from every transplant center within the 250 nm allocation radius or similar definition by the local OPO. * From a Male or female deceased donor, aged 16- 75 years old. * Kidney initially procured, preserved, and packaged with intent to transplant. * LAP provides informed consent for organ donation for transplant and research purposes. * The HTP donor kidney must be allocated to a participating transplant center by a participating OPO, and the transplant center makes the decision to send kidney to Sponsor's central preservation and assessment facility for SNMP assessment and preservation prior to determining suitability for allocation. Donor Kidney Exclusion Criteria: * From a Donor with pre-admission diagnosis of end stage renal failure. * Obvious surgical damage to artery(s), vein(s), or ureter(s) preventing machine perfusion. * From a donor with confirmed HIV (+), HBVSAg (+) and/or HCV NAT (+) serology results. * No LAP consent for both transplant and research purposes. * Cannot arrive to Sponsor's central preservation and assessment facility before reaching 24 hours of cold ischemic time (CIT).

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Edward Hines, Jr. VA Hospital Chicago Illinois
Indiana University Health Indianapolis Indiana
Barnes-Jewish Hospital St Louis Missouri
Erie County Medical Center Buffalo New York
New York University Langone New York New York
The Mount Sinai Hospital New York New York
Duke University Durham North Carolina
University of Wisconsin School of Medicine and Public Health Madison Wisconsin
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06263023 on ClinicalTrials.gov ↗ ← All trials in the USA